Selenomethionine Treatment Does Not Alter Gene Expression in Normal Squamous Esophageal Mucosa in a High-Risk Chinese Population

Nina Joshi,1 Laura Lee Johnson,3 Wen-Qiang Wei,6 Christian C. Abnet,2 Zhi-Wei Dong,6 Philip R. Taylor,4 Paul J. Limburg,7 Sanford M. Dawsey,2 Ernest T. Hawk,5 You-Lin Qiao,6 and Ilan R. Kirsch1

1Genetics Branch, Center for Cancer Research, and 2Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland; 3Office of Clinical and Regulatory Affairs, National Center for Complementary and Alternative Medicine, and 4Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Office of Centers, Training, and Resources, National Cancer Institute, NIH, Bethesda, Maryland; 5Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China; and 6Mayo Clinic College of Medicine, Rochester, Minnesota

Abstract

Selenium is a promising cancer chemoprevention agent. A recent randomized controlled chemoprevention trial found that selenomethionine (SeMet) supplementation for 10 months favorably affected a change in esophageal dysplasia grade among participants who started the trial with mild dysplasia. To further explore the role of SeMet in this trial, we compared gene expression profiles by treatment group using Affymetrix HU 133A chips in before/after supplementation paired normal esophageal biopsies from a subset of 29 trial participants, 16 who received SeMet, and 13 who received placebo. Using \( P < 0.001 \) as a cutoff, 11 differentially expressed genes were found in the SeMet supplementation group but these genes did not include either known selenoprotein genes or genes previously shown to be modulated by selenium treatment. Because the number of differentially expressed genes \((n = 11)\) was less than expected by chance \((n = 18)\), we concluded that SeMet supplementation had no measurable effect on gene expression in the normal squamous esophagus of these subjects with dysplasia. (Cancer Epidemiol Biomarkers Prev 2006;15(5):1046–7)

Introduction

Selenium compounds have been widely studied in the etiology of cancer and as chemoprevention agents because of their potential anticarcinogenic properties (1). Selenium deficiency may play an important role in the etiology of esophageal squamous cell carcinoma in the high-risk population of Linxian, China, where this cancer is endemic and low serum selenium concentrations are strongly associated with increased risk of esophageal squamous cell carcinoma (2). The chemopreventative effects of selenomethionine (SeMet) and celecoxib were recently assessed in a randomized, double-blind, placebo-controlled, 2 × 2 factorial chemoprevention trial conducted in Linxian (3). This trial found that among patients with mild esophageal squamous dysplasia, 10 months of daily treatment with 200 \( \mu \)g SeMet favorably affected a change in dysplasia grade, such that there was less progression and more regression in SeMet recipients compared with participants who did not receive SeMet \((P = 0.02)\). The precise mechanisms underlying the action of SeMet have not been defined. The present study addressed this gap in knowledge by investigating potential changes in gene expression in normal esophageal mucosa from SeMet- and placebo-treated participants of this trial.

Materials and Methods

Details of the chemoprevention trial have been described elsewhere (3). Briefly, asymptomatic adults with histologically confirmed mild or moderate esophageal squamous dysplasia were randomly assigned to one of four intervention groups using a 2 × 2 factorial design. Active treatments were SeMet 200 \( \mu \)g once per day and/or celecoxib 200 mg twice per day. Esophagogastroduodenoscopy examinations with Lugol’s iodine staining were conducted and biopsies were collected and snap frozen before and after a 10-month intervention period.

We compared gene expression in paired histologically normal biopsies from the same individual, one collected at trial baseline \((T_0)\) and the second collected at the end of the intervention period \((T_{10})\), from each of 29 subjects, including 16 who received SeMet supplementation and 13 who received placebo. Serum selenium concentrations were also examined from blood samples collected at baseline and at the end of supplementation using Inductively Coupled Plasma Mass Spectroscopy (4). The study was approved by the Institutional Review Boards of the Cancer Institute, Chinese Academy of Medical Sciences and the U.S. National Cancer Institute.

RNA was extracted from frozen biopsies using standard methods. The small sample RNA amplification protocol described in detail elsewhere was used for this analysis (5). Affymetrix HU 133A chip arrays, consisting of 18,400 transcripts, including 14,500 known genes, were scanned in an Affymetrix GCOS Argon-Ion Scanner at 488 nm. Analyses included probe-level preprocessing using robust multivariate analysis (justRMA) conducted with a 64-bit version of R 1.8.1 and Bioconductor 1.3 on the NIH/CIT Helix System and S-Plus 6.1. To control for multiple comparisons, we considered \( P < 0.001 \) as statistically significant. All tests were two sided.

Received 2/22/06; accepted 3/2/06.

Grant support: Intramural Research Program of the NIH and the National Cancer Institute.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Current address for N. Joshi: U.S.E., Inc., 4401 Dayton-Xenia Drive, Dayton, OH 45432-1894.

Requests for reprints: Ilan R. Kirsch, Amgen, 1201 Amgen Court West, AW1-J 4144, Seattle, WA 98119-3105. Phone: 206-265-7316, Fax: 206-216-5930. E-mail: lkirsch@amgen.com or You-Lin Qiao, Cancer Institute, Chinese Academy of Medical Sciences, Panjiayian, Chaoyang District, P.O. Box 2258, Beijing 100021, P.R. China. Phone: 86-10-6778-1331, ext. 8982; Fax: 86-10-6771-3648. E-mail: qiaoy@public.bta.net.cn

Copyright © 2006 American Association for Cancer Research. doi:10.1158/1055-9965.EPI-06-0135

Table 1. Genes differentially expressed in normal mucosa of the esophagus following SeMet treatment (n = 29 subjects)

<table>
<thead>
<tr>
<th>Gene*</th>
<th>UniGene ID</th>
<th>Difference between SeMet and placebo groups from Tn to T10 (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOD2</td>
<td>HS.384944</td>
<td>143</td>
<td>0.0077</td>
</tr>
<tr>
<td>MAX</td>
<td>HS.42712, HS.497322</td>
<td>130</td>
<td>0.0030</td>
</tr>
<tr>
<td>GNAS</td>
<td>HS.157307</td>
<td>122</td>
<td>0.0054</td>
</tr>
<tr>
<td>C5orf3</td>
<td>HS.166551</td>
<td>116</td>
<td>0.0024</td>
</tr>
<tr>
<td>SCL39A8</td>
<td>HS.284205</td>
<td>112</td>
<td>0.0085</td>
</tr>
</tbody>
</table>

*These genes were statistically significant (P < 0.001) using t tests with unequal variances.

Table 2. Known selenoproteins (n = 25)

<table>
<thead>
<tr>
<th>Selenoprotein</th>
<th>UniGene ID</th>
<th>SeMet treatment differences</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPX1</td>
<td>TR1</td>
<td>DIO3</td>
</tr>
<tr>
<td>GPX2</td>
<td>TR2</td>
<td>SEPP1 NPLX</td>
</tr>
<tr>
<td>GPX3</td>
<td>TR3</td>
<td>SELN</td>
</tr>
<tr>
<td>GPX4</td>
<td>DIO1</td>
<td>SELW</td>
</tr>
<tr>
<td>GPX6</td>
<td>DIO2</td>
<td>SPS2</td>
</tr>
</tbody>
</table>

Two-sample t tests were used to compare the mean of the individual paired T10 minus T0 differences by treatment group.

Results

Expression information for 18,400 transcripts was generated using Affymetrix HU 133 chip A microarrays for 29 subjects with paired histologically normal biopsies from the beginning and the end of the intervention period. At an z level of 0.001, power calculations showed >90% power to detect a 2-fold difference in the expression of any single gene from baseline to 10 months in individuals taking SeMet compared with those taking placebo. T tests revealed only 11 differentially expressed genes with P < 0.001 (Table 1). This is fewer than the number of genes expected to be different by chance alone. That is, at P = 0.001 in an array of ~18,000 targets, on average, 18 genes would be expected to show a significant difference by chance. The list of 11 differentially expressed genes did not include the genes for the 25 previously identified selenoproteins (Table 2) or genes previously identified as being modulated by selenium treatment (Table 3; refs. 6-13). Following 10 months of intervention, the serum selenium concentrations increased substantially (from a median of 84 μg/L to a median of 205 μg/L) in the SeMet-treated individuals (n = 16) but very little in the placebo group (from median of 75 μg/L to a median of 94 μg/L; n = 13).

Discussion

In this analysis, we did not see a difference in gene expression beyond the number of genes likely to be different by chance, despite a substantial increase in serum selenium concentrations and a study size large enough to provide >90% power to detect 2-fold differences in gene expression. Had we used alternative, more conservative statistical adjustment strategies (e.g., Bonferroni or Benjamini-Hochberg), we would have identified no differentially expressed genes. In contrast to our findings, changes in gene expression have previously been reported in the mammary glands of rats treated with methylseleninic acid (10). Differences in species, dose, route of exposure, tissue specificity, and form of selenium may explain this apparent discrepancy in results.

Acknowledgments

We thank the National Cancer Institute/CIT MicroArray Database system and Bioconductor on the National Cancer Institute/CIT Helix system for database and computing support.

References

Selenomethionine Treatment Does Not Alter Gene Expression in Normal Squamous Esophageal Mucosa in a High-Risk Chinese Population

Nina Joshi, Laura Lee Johnson, Wen-Qiang Wei, et al.


Updated version

Access the most recent version of this article at:

[http://cebp.aacrjournals.org/content/15/5/1046](http://cebp.aacrjournals.org/content/15/5/1046)

Cited articles

This article cites 11 articles, 4 of which you can access for free at:

[http://cebp.aacrjournals.org/content/15/5/1046.full.html#ref-list-1](http://cebp.aacrjournals.org/content/15/5/1046.full.html#ref-list-1)

Citing articles

This article has been cited by 2 HighWire-hosted articles. Access the articles at:

[http://cebp.aacrjournals.org/content/15/5/1046.full.html#related-urls](http://cebp.aacrjournals.org/content/15/5/1046.full.html#related-urls)

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.